Maria Palmisano, MD
Corporate Vice President, Translational Development – Clinical Pharmacology, Celgene
Dr. Palmisano joined Celgene in July 2010 as the department head for clinical pharmacology support phase I development in hematology, oncology, immunology and inflammation. She has been focused on enhancing the pharmacology input and increasing the modeling and simulation support for Celgene pipeline compounds. Before joining Celgene, Dr. Palmisano was Vice President, Clinical, Specialty Care Business Unit at Pfizer where she was the line leader for Clinical, supporting all disease areas within the business unit including anti-infectives, inflammation, specialty neuroscience, pulmonary vascular disease, and multi-DA (hematology, transplant, vaccines, bone). Prior to Pfizer, she spent five years at Wyeth as Assistant Vice President, Translational Development & Clinical Pharmacology and then Vice President, Early Development & Clinical Pharmacology, and was the group leader for neuroscience, inflammation and internal medicine/infectious disease sections of Clinical Pharmacology. Dr. Palmisano graduated from UMDNJ New Jersey Medical School with a degree of Doctor of Medicine and completed medical residency at The Medical College of Pennsylvania.